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A B S T R A C T
Cocaine is an illegal drug; its abuse and toxicity are a public health problem due to its high morbidity
and mortality. Cocaine can affect the cardiovascular, central nervous and respiratory systems. The case
of a 42-year-old male without history of chronic or degenerative diseases, but previous cocaine con-
sumption is presented in this report. The patient is admitted to the Emergency Department given that
the clinical presentation included hemoptysis and dyspnea with mild to minimal activity, which evolved
to orthopnea. Advanced airway management was required and supportive care at the Intensive Care Unit
was provided. Imaging studies showed evidence compatible with alveolar hemorrhage diagnosis. In search
of an autoimmune etiology, an antibody-screening panel was requested, reporting negative results for
autoimmune disorders. The patient management was based on corticosteroid therapy and plasmapher-
esis to counter the persistent hemoptysis and hemoglobin serum level decline. The management strategy
was based on the clinical suspicion of vasculitis and a torpid clinical evolution. Pulmonary sepsis ensued,
resulting in patient’s death. The necropsy report describes the primary cause of death as diffuse alveo-
lar hemorrhage secondary to diffuse alveolar injury. This case report presents the detailed clinical, imagining
and histopathological ﬁndings of a patient with alveolar hemorrhage secondary to cocaine consump-
tion, as well as a review of the literature.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Alveolar hemorrhage (AH) is a clinical and pathological syn-
drome characterized by generalized extravasation of red blood cells
into the alveolar space. AH is the most common clinical manifes-
tation of pulmonary vasculitis. Among the clinical manifestations
are hemoptysis and anemia, as well as respiratory failure. Imaging
studies, chest x-ray and/or computed tomography, show evidence
of adiffusealveolar inﬁltrate. Bothautoimmuneandnon-autoimmune
etiologies (e.g. pharmacologic toxicity, infections, idiopathic, and
secondary to cocaine use) have been described in the literature. In
regards to cocaine-inducedAH, acute respiratory symptomsdevelop
within hours of use and include the following: 1) a productive cough;
2) chest pain with or without respiratory distress; 3) hemoptysis;
and 4) asthma exacerbation. These symptoms are more common
with the continuous use of cocaine.1Wepresent the case of a patient
who developed AH associated with cocaine consumption; diag-
nosed clinically and with the assistance of laboratory and imaging
studies. AH is an infrequent pathology; nonetheless, itmust be con-
sidered among patientswith hemoptysis and cocaine consumption.
Other etiologies must be excluded (e.g. vasculitis, bleeding disor-
ders, idiopathic) and the use of glucocorticoids is controversial. The
patient did not respond to glucocorticoid therapy, contrary to other
reports.2 Themain aim of reporting this case is to provide evidence
of a patient that had a torpid evolution refractory to glucocorticoid
therapy resulting in his death.
Case presentation
A 42-year-old male arrived at the Emergency Department com-
plaining of localized pleuritic chest pain with an intensity of 6/10
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on the visual analog scale for pain (VAS). The patient reported he-
moptysis on several occasions, profuse diaphoresis, and dyspnea
with mild to minimal activity six hours prior to admission. The
patient did not allude to any exacerbating or mitigating causes. The
patient was resident of León, Guanajuato, Mexico, single, a con-
struction worker, and had not completed elementary school but was
literate, as educational attainment. The patient’s family history in-
cluded a mother with type 2 diabetes and arterial hypertension;
other relevant aspects of family history were questioned and denied.
Among the patient’s personal history, he reported alcohol abuse and
tobacco consumption formore than 15 years, not being able to quan-
tify the consumption. The patient reported a constant cocaine use
but was unable to quantify his usage, having last used hours prior
to Emergency Department admission. The patient endorsed the use
of industrial solvents such as “Agua celeste” (i.e. heavenly water,
the street name for a sky-blue colored solvent) and adhesives; the
patient was unable to specify the quantity and length of use. The
patient denied a history of allergies, blood transfusions, recent travel,
tattoos, and piercings. Two years ago, the patient suffered a mild
traumatic brain injurywithout complications or sequelae. The patient
had no history of lung disease, asthma during childhood, chronic
or degenerative diseases. Twenty-four hours after admission, the
patient developed type one respiratory insuﬃciency (i.e. vital signs:
BP: 120/80 mmHg, HR: 115 bpm, RR: 32 rpm, Temp: 37°C; arteri-
al blood gas test: pH = 7.3, PaO2 = 55mmHg, PaCO2 = 25mmHg, HCO3-
= 13.9 mEq/L, O2 content = 70%, Base excess = −11.7 mmol/L), thus
requiring invasive artiﬁcial airway with an endotracheal tube and
admittance to the medical intensive care unit for further test and
treatment.
Upon admission, the patient had the following vital signs: BP:
140/70mmHg; HR: 98 bpm; RR: 28 rpm; SO2 with noninvasive ven-
tilation at a rate of 3L/min: 90%; Temp: 36°C; weight: 70Kg; height:
170 cm; BMI: 24.2.
Upon initial physical exploration, we found a patient with
mucosal and tegumentary paleness, recumbent with freely chosen
body position, Glasgow coma score of 15, without focal neuro-
logic deﬁcits nor meningeal sings, aware of his environment, with
reference to place, time, and people. Diaphoretic, skin and mucosal
membranes dehydrated +/+++, with head and neck exploration
without alterations. Upon inspection, the respiratory apparatus
with oral ventilation, tachypnea with thoracic and abdominal
dissociation. The thorax had decreased expansion without vibra-
tions or fremitus during palpation. No asymmetries or abnormal
ﬁndings in tone intensity, pitch, duration, and quality through
direct percussion. Upon auscultation, disseminated bilateral crepi-
tant crackles and bilateral decreased inspiratory breath sounds
at the bases. Precordial auscultation reveals tachycardia, heart
sounds of good intensity without extra heart sounds. Abdominal
exploration without visceromegaly nor abnormalities upon
light and deep palpation. Extremities with ﬁliform pulse aug-
mented in frequency and decreased in amplitude without trophic
changes.
Laboratory results at admission are presented in Table 1. Due
to the personal history of drug use, the following tests were re-
quested: hepatitis B virus, hepatitis C virus, HIV, and urinalysis for
benzodiazepines, barbiturates, cannabis, cocaine, methamphet-
amines, and opiates; all results except urinalysis for cocaine
metabolites were reported as negative. In search of an autoim-
mune etiology, the following tests were requested: Antineutrophil
cytoplasmic antibodies (ANCA), cytoplasmic (cANCA) 0.1 (nega-
tive), perinuclear (pANCA) 0.2 (negative), Anti-glomerular basement
membrane negative, anti-double-stranded deoxyribonucleic acid
0.9UI/ml, anti-cardiolipin IgM antibody 3.20 U/ml and IgG 3.50 U/
ml, cyclic citrullinated peptide antibody <2EU/mL; all reported as
negative (Table 2).
Chest X-ray, posterior-anterior projection, shows bilateral al-
veolar inﬁltrate at the bases, with left predominance and bilateral
progressive diffusion, compatible with ground glass opaciﬁcation
images (Fig. 1). The computed tomography (CT) of the thorax, shows
bilateral posterior and inferior lobular involvement at the alveo-
lar level; images compatible with ground glass opacities and air
bronchogram (Fig. 2).
Clinical evolution
During the ﬁrst week, to treat the anemia (8g/dL), the patient
was transfused two blood bags, increasing hemoglobin levels to
10.2g/dL. Under the clinical suspicion of an autoimmune disease,
three IV boluses of methylprednisolone 1g IV q24h were admin-
istered. Subsequently, insertion of a Mahurkar catheter to initiate
plasmapheresis was performed (i.e. three sessions). The patient con-
tinued with a torpid evolution secondary to active hemorrhage,
which required transfusion of two more blood bags, raising hemo-
globin levels from 8.3g/dL to 10.5g/dL. A hemodialysis session is
conducted as uremia due to secondary hemorrhage was sus-
pected. Ventilation was progressed with extubation after adequate
tolerance was established.
During the second week at the ninth day of hospitalization, the
patient developed temporal, spatial, and personal disorientation
Table 1
Laboratory test results upon admission the Emergency Department
Full Blood Count
Hemoglobin at admission 17.40 g/dL
Hematocrit 51.6%
Erythrocyte count 5.64×106 μL
Platelet count 279,000 μL
Mean corpuscular volume 91.40 fL
Mean corpuscular hemoglobin concentration 33.70g/dL








Urea nitrogen 88 mg/dL
Blood urea nitrogen 40.92 mg/dL
BUN/creatinine ratio 15.3




Aspartate transaminase 20.40 U/L
Alanine transaminase 20 U/L
Lactate dehydrogenase 965.5 U/L
Albumin 2.2g/dL
Alkaline phosphatase 80 U/L
Gamma-glutamyl transpeptidase 40 U/L
Blood Coagulation
Prothrombine time 16.7 sec
Partial thromboplastin time 34.4 sec








526 O. Jiménez-Zarazúa et al. / Heart & Lung 47 (2018) 525–530
without focal neurologic deﬁcits. Polypnea with thoracic and ab-
dominal dissociation elicited reintubation. Persistent fever arose,
prompting the implementation of antimicrobial therapy based on
clinical suspicion of an infection with pulmonary foci. A hyperten-
sive emergency followed, requiring oral and IV management. On
day ten of hospitalization plasmapheresis was initiated. Although
laboratory results reported negative antibody count for autoim-
mune disorders, suspicion of vasculitis remained due to the clinical
presentation. Active hemorrhage obliged for the transfusion of one
unit of packed red cells and blood derivatives. After isolation of En-
terococcus faecium from central and peripheral hemocultures, speciﬁc
antimicrobial therapy was initiated. Two plasmapheresis sessions
ensued as result of active alveolar hemorrhage.
During the third week, on day ﬁfteen of hospitalization, tube tho-
racostomy was performed, placing an endopleural tube on the on
the right mid-axillary line due to the presence of pleural effusion.
Pleural effusion was examined and the report described the pres-
ence of liquid compatible to exudate according to the Light criteria
for pleural effusions.3 Tracheostomy was performed as indicated for
prolonged intubation. Since the patient continued with a drop in
hemoglobin (8.1g/dL), methylprednisolone was reinitiated. A new
hemodialysis session was implemented due to the presence of
uremia (i.e. urea nitrogen of 170 mg/dL and creatinine of 3.15 mg/
dL). Boluses of methylprednisolone were initiated due to the
emergency and severity of the clinical presentation; following
the protocol for AH secondary to a probable autoimmune etiolo-
gy. The patient presented a torpid clinical and paraclinical evolution,
thus auxiliary plasmapheresis sessions were added to limit the clin-
ical deterioration. However, due to the persistence of AH, more
methylprednisolone boluses were initiated without clinical im-
provement. The patient continued with a torpid evolution, hence
a pulmonary biopsy was requested. Through the histopathologi-
cal examination of tissue biopsy, the diagnosis was diffuse AH (Fig. 3
and Fig. 4).
On the twentieth day of hospitalization, the patient presented
extreme bradycardia (30 BPM), progressing to asystole. Advanced
life support protocol was initiated and after 20 minutes without
reverting the cardiac arrest; the patient was pronounced de-
ceased. Necropsy examination was performed (Fig. 5). The necropsy
report describes the primary cause of death as diffuse alveolar hem-
orrhage secondary to diffuse alveolar injury. The probable
predisposing factor was cocaine consumption. The following ﬁnd-
ings were concomitant alterations reported in the necropsy report:
unspeciﬁc acute bronchopneumonia without signs of vasculitis or
capillaritis or intraalveolar cocaine crystals; panacinar emphyse-
ma; and acute renal failure.
Discussion
Alveolar hemorrhage (AH) is a medical emergency that re-
quires a timely diagnosis and an etiology-speciﬁc treatment. Even
when AH is appropriately recognized, mortality is high.4 Symp-
toms appear throughout the days; however, a subacute onset has
also been reported.5 The clinical presentation involves hemopty-
sis (i.e. two-thirds of reported cases report it), fever, cough, and
dyspnea. Exclusion of common etiologies, as well as the integra-
tion of signs, symptoms, blood tests, and auxiliary imaging tests are
the basis of the clinical diagnosis. Among the causes of hemopty-
sis that must be excluded are pneumonia and pulmonary
neoplasms.6,7
If undiagnosed or treated in a timely manner, diffuse alveolar
hemorrhages can have catastrophic results. Small pulmonary vessel
vasculitis is the primary source of AH. Alveolar hemorrhages can
be classiﬁed into three main groups: 1) pauci-immune, generally
associated to capillaritis and ANCA positivity; 2) produced by
Table 2
Supplementary laboratory test results
Follow-up
Hemoglobin at 24 hours 11.7 g/dL
Hemoglobin at 5 days 8 g/dL
Hemoglobin at 5 days after blood transfusion 10.2 g/dL
Hemoglobin at 8 days 8.3 g/dL
Hemoglobin at 8 days after blood transfusion 10.5 g/dL
Hemoglobin at 15 days 8.1 g/dL
Creatinine at 48 hours 3.7 mg/dL
Urea nitrogen at day 15 170 mg/dL
Creatinine at day 15 3.15 mg/dL
Antibodies
Cytoplasmic antineutrophil cytoplasmatic antibodies (cANCA) 0.1
Perinuclear antineutrophil cytoplasmatic antibodies (pANCA) 0.2
Anti-glomerular basement membrane Negative
Anti-double-stranded deoxyribonucleic acid 0.9 UI/ml
Anti-cardiolipin IgM antibody 3.20 U/ml
Anti-cardiolipin IgG 3.50 U/ml
Cyclic citrullinated peptide antibody <2 EU/mL
Viral panel
Hepatitis B virus Negative
Hepatitis C virus Negative






Ketones, glucose, and nitrite Negative
Leukocytes 1 per high power ﬁeld
Erythrocytes 3 per high power ﬁeld







Fig. 1. Chest X-ray. Posterior-anterior projection. Bilateral alveolar inﬁltrates at the
bases, with left predominance and bilateral progressive diffusion, compatible with
ground glass opaciﬁcation images.
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immune deposits, which can be identiﬁed by immunoﬂuores-
cence; and 3) a diverse group, that includes etiologies such as
pharmacologic toxicity, infections, and idiopathic causes.8,9
Among the infectious etiologies that must be considered are In-
ﬂuenza A virus subtype H1N1, Dengue virus, Leptospirosis, and
Staphylococcus aureus. Immunosuppressive medication associated
with AH are alemtuzumab, cytarabine, azathioprine, bevacizumab,
cyclophosphamide, erlotinib, etoposide, rituximab, and mitomy-
cin C, among others.10,11 Other medications or substances that are
reported to have direct pulmonary damage include amiodarone,
Fig. 2. Computed tomography (CT) of the thorax. Bilateral posterior and inferior lobular involvement at the alveolar level; images compatible with ground glass opacities
and air bronchogram. A and B) Axial plane CT without contrast, mediastinal window, areas of alveolar involvement at the posterior and inferior lobules in bilateral hemi-
thorax. B) Regions of consolidation associated with air bronchogram. C and D) Axial plane CT of the thorax without contrast, lung window. C) Pulmonary apical regions
with ground glass opacities identiﬁed bilaterally. D) Lower level axial planes, where ground glass opacities can also be identiﬁed, coalescing into regions of consolidation
associated with air bronchogram.
Fig. 3. Histopathology. Lung, 50x, hematoxylin and eosin staining. Diffuse alveolar
damage is observed to the right with abundant erythrocytes inside the alveolar spaces.
To the lower left of the image, a bronchiole with abundant polymorphonuclear cells
are observed. Diffuse alveolar hemorrhage secondary to alveolar injury associated
with bronchopneumonia.
Fig. 4. Histopathology. Lung, 100x, hematoxylin and eosin staining. Diffuse alveo-
lar damage is observed with pneumocyte degeneration and hyaline appearance in
the alveolar wall with numerous erythrocytes inside the alveolar spaces.
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nitrofurantoin, chemotherapeutic agents, and cocaine, among
others.4,12 Conditions such as thrombocytopenia and hypersensi-
tivity intolerance are associated with AH. Medications that alter
blood coagulation such as thrombolytics, anticoagulants,
antiaggregant drugs, and dextran 70 are associated with throm-
bocytopenia. Propylthiouracil, phenytoin, sulfasalazine, hydralazine,
carbimazole, leukotriene antagonists, and penicillin are among the
medications that have been associated with hypersensitivity
reactions.13
Cocaine abuse and overdose have a high morbidity and mor-
tality, sustaining damage to the cardiovascular, central nervous and
respiratory systems.14 Cocaine has sympathomimetic, local anes-
thetic, and vasoconstrictive effects. Endothelial damage secondary
to cocaine intake is primarily caused by its vasoconstrictive effects.
The vasoconstrictive effect of cocaine results from α-adrenergic re-
ceptor stimulation on arteriolar smooth muscle cells, as well as the
up-regulation of endothelin-1 and autocrine down-regulation of
nitric oxide.15 These vasoconstrictive properties have been associ-
ated with ischemia and endothelial damage in AH.15 Cocaine has
a direct toxic effect over capillary endothelin, thus leading to cap-
illary congestion and pulmonary edema. Subsequent formation of
free radicals and production of transforming growth factor beta (TGF-
β), can lead to pulmonary ﬁbrosis and pulmonary hypertension; due
to the anabolic collagen properties of TGB- β, as well as in situ
thrombosis in chronic cocaine users.16 Other hematologic alterations
that have been associated with cocaine consumption are throm-
bocytopenia and transient protein C and S deﬁcits.1
Among the differential diagnoses for acute pulmonary lesions
secondary to cocaine consumption are: 1) crack cocaine acute pul-
monary toxicity; 2) acute eosinophilic pneumonia; 3) acute
respiratory distress syndrome (e.g. infectious, aspiration events, and
trauma); 4) pulmonary embolism; 5) heart failure; 6) pneumo-
nia; and 7) acute coronary syndrome.1,14,17 Toxicity due to chronic
cocaine use should be differentially screened for interstitial lung
disease (e.g. pneumonia, lymphatic carcinomatosis, and pneumo-
coniosis), chronic granulomatous disease (e.g. sarcoidosis, berylliosis,
andmiliary tuberculosis), and chronic obstructive pulmonary disease
(e.g. tobacco smoking-induced emphysema).1,5
Imaging ﬁndings depend on the length of AH presentation. In
acute phases, 20% to 50% of cases can have normal lung imaging.
Central and basilar opacities might be present in chest x-rays,
without costophrenic angle blunting. No interlobular septal thick-
ening is visualized associated with these opacities in a CT scan.12,17
A bronchoscopy with bronchoalveolar lavage is necessary for AH
cases as it provides conﬁrmatory ﬁndings of intraalveolar hemor-
rhage, as well as suitable samples to assess infectious etiologies.
Alveolar bleeding with more than 20% of hemosiderin-laden al-
veolar macrophages (i.e. dust cells) provides additional evidence
for AH diagnosis.8
Treatment for the pulmonary complications of cocaine abuse is
based on the observations made in case reports.16 Initially, discon-
tinuation of cocaine along with supportive care is provided to the
patient.14 Invasive mechanical ventilation is required in 27% of the
cases that present respiratory failure associated with hemody-
namic instability, hypervolemia, as well as acute renal injury
secondary to AH.7 The use of corticosteroids is controversial. Some
case reports suggest that certain cocaine-induced AH improve with
their implementation5,16; while other case reports suggest no beneﬁt
is gained by the use of corticosteroids.14
A vast array of complications associated to cocaine inhalation
are described: 1) interstitial pneumonitis; 2) interstitial ﬁbrosis; 3)
pulmonary hypertension; 4) diffuse alveolar hemorrhage; 5) diffuse
alveolar injury; 6) asthma exacerbation; 7) barotrauma; and 8)
airway lesion secondary to thermic insult.16,18
Conclusion
Alveolar hemorrhage associated with cocaine consumption is a
diﬃcult pathology to diagnose. This non-immune etiology must be
considered among the possible causes of AH due to the high con-
sumption and mortality rates of cocaine in the recent decades. This
etiology must be suspected in patients with a history of cocaine
use, who present hemoptysis, and develop anemia as part of their
clinical presentation. Additionally, AH secondary to cocaine con-
sumption should be suspected among patients with imaging studies
showing pulmonary inﬁltrates. This case had a torpid evolution sec-
ondary to sepsis, with pulmonary foci, thus progressing to death
despite optimal treatment. Previous reports involving cocaine users
show an increased risk of infections secondary to decreased lym-
phocyte andmacrophage activity, as well as mucociliary clearance.19
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